AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Camostat
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Study NCT03376828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Endotracheal intubation time using the Macintosh laryngoscope
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAB-185 (low dose)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986414 + BMS-986413
Description: Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AZD7442 (IV)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AZD7442 (IM)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT03491072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
Study NCT03491072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive IV fentanyl
Study NCT03491072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients will receive IV fentanyl
Study NCT01183910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrus Bioflavanoid Blend
Description: Pill Taken Twice a Day
Study NCT01183910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Oral Tablet Taken Twice a Day
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAB-185 (high dose)
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT02889380 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bamlanivimab 700mg
Description: Administered by single IV infusion. Participants are no longer being randomized to this intervention.
Study NCT01117545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: Six sessions of EFT
Study NCT03376828 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Endotracheal intubation time using the Macintosh laryngoscope
Study NCT03376828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac Videolaryngoscope
Description: Endotracheal intubation time using the C-Mac Videolaryngoscope
Study NCT03376828 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: C-Mac Videolaryngoscope
Description: Endotracheal intubation time using the C-Mac Videolaryngoscope
Study NCT03007277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANJO
Description: PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
Study NCT00153530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy
Study NCT00153530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy
Study NCT00153530 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: whole-brain irradiation
Study NCT00852020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutrition supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks
Study NCT00852020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral nutrition supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks
Study NCT00609674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Description: Fluticasone furoate nasal spray
Study NCT00609674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02687126 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Central Venous Catheterization
Description: Ultrasound guided internal jugular venous catheterization
Study NCT04134091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1144 Formulation A
Description: Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
Study NCT03007277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PANJO
Description: PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
Study NCT02331264 — intervention group
Intervention type: OTHER
Intervention: Exposure to metal debris
Description: The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
Study NCT02112110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT02112110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-BMS-791325
Study NCT04107220 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sacubitril/Valsartan
Description: Effect of Sacubitril/Valsartan on BNP and NT-proBNP
Study NCT02028949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavedos®
Study NCT02028949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT00594399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling
Description: Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
Study NCT01440101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab (BG00002)
Study NCT01440101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04706572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation with external auditory bio-feedback
Description: Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
Study NCT04706572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stimulation with external auditory bio-feedback
Description: Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
Study NCT04134091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1144 Formulation B
Description: Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
Study NCT04134091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo capsule administered as BID
Study NCT00505622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study NCT04138368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dyadic psychotherapeutic intervention
Description: Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
Study NCT04138368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supportive intervention
Description: Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
Study NCT03774303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: A mobile application that will be used to prepare families for day surgery
Study NCT03774303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: current practice
Description: the current practice used to prepare families for day surgery
Study NCT03393208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GIR
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study NCT02516930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: crowdsourced video
Description: video promoting condom use
Study NCT02516930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: social marketing video
Study NCT02388776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
Study NCT00016315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00016315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT03393208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GIR
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study NCT01668602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Walking with Fast Functional Electrical Stimulation (FES) Training
Description: Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.
Study NCT01668602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Walking
Description: Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
Study NCT04062045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hcl 0.2% Inj Vil 10Ml
Description: Group A will receive the medicine through the erector spinae catheter.
Study NCT04062045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Group B will receive Saline 0,9% through the erector spinae catheter.
Study NCT00741858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duragen duraplasty
Description: Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
Study NCT00741858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duraguard duraplasty
Description: Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
Study NCT02871102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver with PEEP and Tidal Volume Optimization
Description: A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
Study NCT02603055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg/0.5ml Hepatitis E vaccine
Description: three doses, 30μg/0.5ml per dose
Study NCT00692796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
Study NCT02690376 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Assisted Capsule Endoscopy
Description: Swallowed magnetic capsule for endoscopy purposes
Study NCT02603055 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 30μg/0.5ml Recombinant Hepatitis E vaccine
Description: 30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
Study NCT03192722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Colored near reading glasses
Description: Participants are provided with colored near vision glasses.
Study NCT03192722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colored near reading glasses
Description: Participants are provided with colored near vision glasses.
Study NCT03192722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lighting as determined by LuxIQ/2 or OttLite Cobra
Description: Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
Study NCT02431000 — intervention group
Intervention type: PROCEDURE
Intervention: Sperm and blood collected for analysis
Description: Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
Study NCT04421716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Ursolic Acid 150mg
Study NCT04421716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600mg
Study NCT01033877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TdaP vaccine SSI
Description: 1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
Study NCT01033877 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td vaccine SSI
Description: 1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d)
Study NCT02129894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal Binder
Description: placement of abdominal binder
Study NCT03630471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIDE 'Step 1' problem-solving intervention
Description: The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home.
Study NCT03630471 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
Study NCT00096291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin followed by Paclitaxel
Description: Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin
Study NCT03611660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Healthy Lifestyle Program
Description: Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
Study NCT03611660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Healthy Lifestyle Program
Description: Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
Study NCT03611660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Instruction
Description: Participants receive six mindfulness sessions.
Study NCT02098551 — intervention group
Intervention type: OTHER
Intervention: SPT and APT
Description: All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone.
Study NCT00174668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
Study NCT00174668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Therapy
Description: NPH (70%) plus regular insulin or insulin aspart (30%)
Study NCT00016315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT04088630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
Study NCT00016315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04088630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral placebo pill within 24 hours of symptom onset
Study NCT04088630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Fingolimod
Description: A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset
Study NCT00201851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: 20 mg po daily x 5 years
Study NCT00201851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg po daily x 5 years